Revacept, a novel inhibitor of platelet adhesion in patients with stable coronary artery disease undergoing elective percutaneous coronary interventions: A phase II, multicentre, randomised, dose-finding, double-blind and placebo-controlled study.

Trial Profile

Revacept, a novel inhibitor of platelet adhesion in patients with stable coronary artery disease undergoing elective percutaneous coronary interventions: A phase II, multicentre, randomised, dose-finding, double-blind and placebo-controlled study.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs PR 15 (Primary)
  • Indications Coronary artery disease
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 14 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top